研究 & 发展
科学与
一个目的
千亿体育官网的方法
千亿体育官网的R&D approach is grounded in a thoughtful focus on real-world challenges faced by people living with complex and serious diseases. 透过这个镜头, we seek to develop innovative medicines in neuroscience and oncology that can bring value to patients.
Our scientists are focused on developing new molecules that leverage well-validated biological pathways, utilizing our expertise in advanced medicinal chemistry and protein engineering, 再加上纪律严明的, 综合研究方法.
关键的专利候选产品管道
We have a pipeline of product candidates in development for psychiatric and neurological disorders and cancer. These programs are investigating treatments or outcomes that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.
- 发现
- 临床前
- 第一阶段
- 第二阶段
- 第三阶段
-
神经科学
-
奥氮平和samidorphan 精神分裂症或双相I型障碍(儿科)
-
Alks 2680 - 猝睡症
-
食欲素激动剂 Non-Orphan迹象
-
-
肿瘤学
-
Nemvaleukin α * - 铂耐药卵巢癌
-
Nemvaleukin α 黏膜黑色素瘤
-
IL-12
-
IL-18
-
最后更新:2023年7月
科学平台
展望未来，千亿体育官网将采用“从病床到工作台”的方法来开发R&D – reversing the typical thought process and beginning with real-world, unmet patient needs that inform our work as we seek to develop new treatments in the areas of neuroscience and oncology. Our drug development efforts are focused on two scientific research platforms with broad potential.
突触功能障碍
千亿体育官网的突触功能障碍平台旨在改善这种结构, 突触的功能和环境. Improvement of synaptic integrity and function has the potential to slow progression, 并保持认知和功能能力, 在多种神经和精神疾病中.
肿瘤中的免疫调节
Our immuno-oncology platform is designed to harness the power of the immune system to fight cancer. We are developing novel cytokine-based therapies designed to increase visibility of tumor cells to the immune system, increase the tumor-killing potential of CD8+ T and Natural Killer cells, 并去除肿瘤微环境中的抑制信号. Nemvaleukin阿尔法, 千亿体育官网最先进的实验性免疫治疗候选药物, 是用这个平台开发的吗.
技术 & 功能
We leverage our proprietary technologies and molecular design capabilities to design innovative medicines with distinct therapeutic properties.
长效技术
Our suite of long-acting injectable technologies enables the gradual release of small molecules as well as complex macromolecules into the body at a controlled rate over a specific period of time. 其中包括mediorb®, LinkeRx® 和纳米晶体®.
口服控释技术
千亿体育官网的定制种类繁多, 固体口服给药技术, 包括口服缓释, 延长释放, 速, pulsatile-release and chrono-timed delivery enable us to customize specific drug-release profiles and dosage forms.
蛋白质工程
We are harnessing our established protein engineering platforms to develop novel cytokines with the potential to fight cancer.
分子设计
We have built a sophisticated molecular design toolbox to support our small molecule and biologics projects. 这包括先进的分子动力学模拟, 量子化学计算, 人工智能和专有的机器学习模型.
研究者赞助的研究
We seek to support investigator research designed and conducted by independent clinicians and scientists. Since the onset of our 研究者赞助的研究 (ISS) program in 2008, 千亿体育官网已经支持了40多个临床试验.
千亿体育官网路径研究奖®
千亿体育官网路径研究奖® is a competitive grant program for the next generation of researchers working on the front lines to advance understanding and awareness of disease states in the field of neuroscience.
医学教育补助金
We contribute to independent education by supporting medical education grants. Our focus areas include accredited educational activities with pragmatic approaches to improve patient care and public health in the areas of schizophrenia, 双相情感障碍和酒精使用障碍.
作为一名研究者, one of the most exciting things I do is coming up with ideas that will affect patients in the long-term. 我的工作是找出千亿体育官网如何能产生最大的影响.
劳拉·谭
研究科学家
临床试验
Alkermes is committed to researching and developing innovative medicines that can help address unmet needs of patients and their families. 临床试验是这一过程的关键部分, during which we seek to determine the safety and efficacy of an investigational medicine or build further understanding of a marketed medicine.
For information about ongoing clinical trials using Alkermes’ marketed or investigational medicines, 请咨询美国国立卫生研究院网站, www.临床试验.Gov，它包含一个可搜索的数据库.